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Effect of ultrafiltration during hemodialysis
on hepatic and total-body water:
an observational study
Claire J. Grant1, Trevor P. Wade2, Charles A. McKenzie2, Guido Filler1,3,4,5,6, Christopher W. McIntyre1,2,3,4,5
and Shih-Han S. Huang1,2,3,4,5*
Abstract
Background: The hepatic circulation is involved in adaptive systemic responses to circulatory stress. However,
it is vulnerable to both chronic hypervolemia and cardiac dysfunction. The influence of hemodialysis (HD) and
ultrafiltration (UF) upon liver water content has been understudied. We conducted a detailed pilot study to
characterize the effects of HD upon liver water content and stiffness, referenced to peripheral fluid mobilization
and total body water.
Methods: We studied 14 established HD patients without liver disease. Magnetic resonance imaging (MRI) together
with ultrasound-based elastography and bioimpedance assessment were employed to measure hepatic water
content and stiffness, body composition, and water content in the calf pre- and post-HD.
Results: Mean UF volume was 8.13 ± 4.4 mL/kg/hr. Fluid removal was accompanied with effective mobilization of
peripheral water (measured with MRI within the thigh) from 0.85 ± 0.21 g/mL to 0.83 ± 0.18 g/mL, and reduction in
total body water (38.9 ± 9.4 L to 37.4 ± 8.6 L). However, directly-measured liver water content did not decrease
(0.57 ± 0.1 mL/g to 0.79 ± 0.3 m L/g). Liver water content and IVC diameter were inversely proportional (r = − 0.57,
p = 0.03), a relationship which persisted after dialysis.
Conclusions: In contrast to the reduced total body water content, liver water content did not decrease post-HD,
consistent with a diversion of blood to the hepatic circulation, in those with signs of greater circulatory stress.
This novel observation suggests that there is a unique hepatic response to HD with UF and that the liver may
play a more important role in intradialytic hypotension and fluid shifts than currently appreciated.
Keywords: Chronic hemodialysis, Ultrafiltration, Intradilyatic hypotension, Fluid overload, Magnetic resonance imaging
Background
Determining the appropriate fluid balance is often chal-
lenging in hemodialysis (HD) patients. Fluid overload is
common and is associated with increased risk of cardio-
vascular morbidity and mortality [1, 2]. By contrast,
excessive fluid removal can lead to myocardial stunning,
a reversible functional impairment of the myocardium
due to ischemic injury which has been shown to be dir-
ectly related to the degree of hemodynamic stress during
dialysis [3]. Recurrent stress of this nature leads to pro-
gressive cardiac dysfunction as well as ischemic injury in
other organs, including the brain [4, 5].
The liver is a central organ which receives a high pro-
portion of cardiac output and holds a significant volume
of blood (10–15% of total blood volume) [6]. It has a
role in the maintenance of hemodynamic stability during
circulatory stress by releasing some of this held blood to
support the circulating volume [7]. It is also vulnerable
to chronic hypervolemia, hypovolemia and endotoxemia,
all of which are common in hemodialysis patients [8, 9].
Few studies have assessed the hepatic-splanchnic vascu-
lar system in end-stage renal failure, however, there has
not been reported studies to evaluate the impact of fluid
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overload and ultrafiltration on liver water content [10–12].
Liver congestion can be quantified by a new magnetic res-
onance (MR) technique at our centre. Our aim with this
present pilot study was therefore to determine the impact
of hemodialysis upon hepatic congestion and explore the
hepatic hemodynamic response to hemodialysis. Our ob-
jective was to assess the hepatic responses, which include
the changes in liver water, liver stiffness and liver enzymes,
to fluid removal during HD. We hypothesized that liver
water would decrease during HD. In addition, we hypothe-
sized that liver stiffness would decrease after HD.
Methods
Ethical approval
This observational study was approved by the Health
Sciences Research Ethics Board at the University of
Western Ontario (HSREB106868) and conducted ac-
cording to the GCP/ICH guidelines and the Declaration
of Helsinki.
Study population
Patients from the prevalent chronic HD population cared
for in the London Regional Renal Program (Ontario,
Canada) were recruited to a cross-sectional study and
written consent was obtained from all patients. For inclu-
sion, patients had to have been receiving dialysis for at
least 3 months. Exclusion criteria included the presence of
liver disease or known risk-factors for liver disease (viral
hepatitis, history of significant alcohol intake), contraindi-
cations to MR scanning (for the sub-study) and history of
lower limb amputation. In addition, if the patients had any
signs of inflammation, infection, maglignancy, and/or
hemodynamic instability, they were excluded.
Baseline information was obtained for each subject, in-
cluding age, gender, height, blood pressure, underlying
renal disease, dialysis information (frequency, blood flow
rate, dialysate flow rate, ultrafiltration volume, duration of
dialysis session, and single-pool Kt/V urea measurements),
and most recent residual renal function measurement.
Prior to and after their routine HD treatments, all
subjects underwent clinical assessment of fluid status
30–60min prior to their HD treatment. Multi-frequency
bioimpedance analysis of total body water and magnetic
resonance imaging (MRI) scans in supine position were
also performed during this period. In addition, blood
samples were taken to measure biomarkers such as
hematocrit, creatinine, urea, bilirubin, liver enzymes,
and sodium levels.
Bioimpedance analyzer were performed using the
standard tetrapolar technique, with electrodes placed at
both wrists and both ankles after subjects lay supine for
at least 10 min (50 frequencies (5 to 1000 kHz), Body
Composition Monitor®, Fresenius Medical Care Deutschland
GmbH) [13].
Organ water content was quantified pre- and post-
dialysis using 3D chemical shift encoded MRI (CSE-MRI)
pulse sequence implemented on a 3 Tesla MRI scanner
(MR 750, GE Healthcare, Waukesha, WI) [14]. This tech-
nique has been validated in clinical studies and employed
in large randomized-controlled trials [15–17]. Imaging pa-
rameters were selected to cover the abdomen with proton
density contrast: Field Of View (FOV) = 48x34x58 cm [3],
matrix = 128x90x72, repetition time (TR) = 4.7ms, flip
angle = 3 deg. The acquisition was accelerated using ARC
(autocalibration reconstruction for Cartesian imaging) in
the phase and slice directions with a 32 channel Torso
array for an overall acceleration factor of R = 3.9, permit-
ting a complete volume to be acquired in a sub 20s breath
hold. The images at the 6 echoes (echo time (TE) (ms)
= [0.37 0.76 1.14 1.152 1.90 2.28]) were receive sensitivity
corrected and processed to give water only and fat only
images. Organ water content was then evaluated by
drawing regions of interest (ROI) in each organ and
normalizing by comparing with a water phantom that was
included in the field of view [18]. For the hepatic ROI, we
select the right lower lobe with 1 cm margin to exclude
splanchnic vascular bed (Fig. 1). We also avoided the
portal and hepatic vasculature. For the peripheral muscle
water content, unaccelerated, high resolution, 3D CSE-MRI
images (FOV= 48x38x48, matrix = 192x160x80) were also
acquired of the thigh with otherwise similar parameters
and processing, to quantify muscle water content. Finally,
the infectior vena vaca (IVC) diameter was measured in an
axial T2 weighted fast spin echo slice (FOV= 48 cm,
thickness = 8mm, matrix = 384 × 160, TE = 80ms) approxi-
mately 5 cm below the diaphragm. Diameters were mea-
sured by two readers and averaged.
Measures of liver stiffness were obtained by a single,
trained operator (CG) using transient elastography
(Fibroscan® GE Healthcare) [19]. Measurements were
obtained by the conventional clinical method, with the
subject supine and 10 valid measurements obtained with
the median value recorded. Unreliable results were
deemed as those with an IQR of less than 33% of the
median or in those in whom fewer than 10 valid results
could be obtained.
All these measurements and assessments were repeated
30–60min after their HD treatment.
Statistical analysis
Data were analyzed using SPSS Version 22 (IBM,
Chicago, US). All data were tested for normality using
the Shapiro-Wilk test. Parametric data are described
using the mean ± 1 standard deviation (SD) whereas
non-parametric data were expressed using the median
(interquatile range, IQR). Comparisons of continuous
outcomes between two groups were performed using the in-
dependent t test for parametric data and Mann Whitney U
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test for non-parametric data. Comparisons of related
outcomes at two different time points were performed
using the paired t-test for parametric data and the
Wilcoxon signed-rank test for non-parametric data.
Bivariate correlation was assessed using Pearson’s
correlation coefficient for parametric data and Spearman’s
coefficient for non-parametric data. An alpha error of
less than 5% (p < 0.05) was considered to be statisti-
cally significant.
Results
Study population
Eighteen patients consented to be part of the study from
February 2015 to April 2016. Two subjects were ex-
cluded due to the presence of exclusion criteria. One
subject was excluded from the analysis due to the diag-
nosis of metastatic cancer. Poor data quality meant that
liver MRI data was not available for one subject. Four-
teen subjects for whom liver MRI data was available
formed the study population.
Characteristics of the study population are shown in
Table 1. The majority of patients were male and had
either diabetic or hypertensive nephropathy as the
underlying etiology of their renal disease. Other eti-
ologies included unspecified nephrotic syndrome (1)
obstructive uropathy (1), lupus nephritis (1), renal
dysplasia associaved with Prune-Belly syndrome
(1) and IgA nephropathy (1). The majority of patients
(86%) were dialyzed via central catheter access with
the remainder via peripheral fistula access. Echocar-
diographic of all these patients showed normal ejec-
tion fraction (EF) > 55–60% except one patient who
had EF 35–40%.
All subjects underwent their prescribed length of
dialysis session as part of the study. Ultrafiltration volumes
ranged from 0 to 4090mL (mean 8.13 ± 4.4mL/kg/hr).
Two patients experienced symptomatic intra-dialytic
hypotension (IDH), with dizziness or severe cramps.
Three subjects had IDH defined as a nadir systolic blood
pressure of less than 100mmHg, whilst six subjects
experienced a fall in systolic blood pressure of at least
40 mmHg during dialysis.
Fig. 1 Water image from CSE-MRI reconstruction showing the
Region of Interest (ROI) in the liver for which liver water content was
computed. ROIs were drawn to avoid major vessels, and regions
which contained water-fat swaps. A water phantom is shown in the
lower left, which was used for normalization to obtain absolute.
These two images were from Patient 14. Top: pre-dialysis (0.7) and
bottom: post-dialysis (0.83)
Table 1 Study Population Characteristics
Age (yrs) 58.6 ± 18
Gender (M/F) 13/1
BMI (g/m2) 23.8 ± 2.6
Diabetes (Y/N) 5/9
Known CAD (Y/N) 5/9
Aetiology of ESRF (DM/HTN/Other) 5/3/6
ACEi/ARB (Y/N) 5/9
Calcium channel blocker (Y/N) 10/4
Beta blocker (Y/N) 10/4
Alpha blocker (Y/N) 2/12
Diuretic (Y/N) 6/8
Use of ESA (Y/N) 10/4
Time on dialysis (months) 9 (4–172)
Time receiving HD (months) 6 (1–172)
Previous transplant (Y/N) 4/10
Current HD access (CVC/AVF) 12/2
Hemoglobin (g/L) 107 ± 13
Haematocrit (L/L) 0.324 ± 0.04
Sodium (mmol/L) 136 ± 3.9
Albumin (g/L) 38.5 ± 6.2
Bilirubin (μmol/L) 4.19 ± 1.2
M male, F female, Y yes, N no, CAD coronary artery disease, ESRF end-stage
renal failure, HTN hypertension, DM diabetes, ACEi angiotensin converting
enzyme inhibitor, ARB angiotensin receptor blocker, ESA erythopoeisis-
stimulating agent, CVC central venous catheter, AVF arteriovenous fistula.
All blood results represent pre-dialysis values
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Measures of hepatic water and central volume
Mean pre-dialysis hepatic water content was 0.63 ± 0.19 g/mL
(range 0.34 g/mL to 1.05 g/mL). There was no association be-
tween hepatic water and clinically or bioimpedance-derived
measures of hypervolemia. There was also no signifi-
cant relationship between liver stiffness and hepatic
water content (r = − 0.02, p = 0.93; Table 2). Higher
hepatic water content was, however, associated with a
smaller IVC diameter (r = − 0.57, p = 0.03) (Fig. 2) and
with a higher pre-dialysis hematocrit (r = 0.61, p = 0.048).
The mean liver stiffness values were 5.0 ± 2.07 kPa and
6.3 ± 2.31 kPa pre and post-hemodialysis (p = 0.20).
There was no statistically significant change in the mean
liver water content after HD (from 0.63 ± 0.2 g/mL to
0.70 ± 0.2 g/mL, p = 0.34) (Fig. 3). The liver water con-
tent increased in eight subjects but fell in the remaining
six subjects. The magnitude of the change in liver water
content pre- and post- hemodialysis was not associated
with ultrafiltration volume (r = − 0.04, p = 0.88) (Fig. 4)
or the change in liver stiffness values (r = 0.06, p = 0.84).
There were no clear clinical factors which were signifi-
cantly associated with the direction of change in liver
water content, including age, co-morbidity or fluid status
before dialysis. However, liver water content rose in all
patients with intra-dialytic hypotension, which was
defined as > 40mmHg drop in blood pressure with/without
symptoms and/or a nadir blood pressure < 100mHg based
on previous studies [20]. Furthermore, there was a greater
increase in liver water content in those whose systolic blood
pressure fell by more than 40mmHg during dialysis
(0.21 ± 0.2 g/mL vs. -0.04 ± 0.2 g/mL, p = 0.05) (Fig. 3).
IVC diameter did not change significantly after
dialysis. Nevertheless, the correlation between liver
water content and IVC diameter persisted (r = − 0.60,
p = 0.03). Pre-dialysis IVC diameter was lower in those who
suffered IDH, with a nadir blood pressure < 100mHg,
(2.02 ± 0.17 cm vs 1.69 ± 0.14 cm, p = 0.009).
Peripheral and Total body water content
Pre-dialysis, total body water was 39.0 ± 9.4 L with
intra-dialytic weight gains of between − 3 and 5.9 kg with
median weight gain of 1.65 kg. One subject was 3 kg
under their target weight prior to dialysis and bio-
impedance measured that he was 1.2 L below his ideal
fluid status. Full bioimpedance analysis was unobtainable
in the one subject who demonstrated clinically signifi-
cant fluid overload, being almost 6 kg over the target
weight with profound peripheral edema. Pre-dialysis
MRI-measured limb (thigh) water content was associ-
ated with a higher total body water (r = 0.59, p = 0.06),
higher intracellular water volume (r = 0.64, p = 0.02) and
a higher diastolic blood pressure (r = 0.70, p = 0.02).
Table 2 The relationship between ultrafiltration, liver stiffness and liver water content
Patient Number Ultrafiltration volume (mL) % change in MRI water % change in liver stiffness
1 0 80% 27%
2 200 −5% 12%
3 1200 26% −17%
4 1400 −52% 25%
5 1600 21% −10%
6 1800 126% 115%
7 2100 −30% 5%
8 2340 22% 33%
9 2400 0% 50%
10 2800 −3% 26%
11 2900 −21% 0%
12 3500 32% −20%
13 3600 37% 9%
14 4090 9% −59%
Fig. 2 FSE image indicating the inferior vena cava and abdominal
aorta, and themajor diameter of each
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Fig. 3 Relationship between liver water content and IVC diameter pre-dialysis
Fig. 4 Change in liver water content with dialysis and the relationship with haemodynamic stability during HD. a: Liver water before and after
dialysis. b: Liver water and fall in blood pressure c: Liver water and nadir blood pressure. d: IVC diameter and nadir blood pressure
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After dialysis, total body water fell by a mean of 1.59 L
to 37.4 ± 8.4 L and thigh water content decreased from
0.85 ± 0.21 g/mL to 0.83 ± 0.18 g/mL, although this was
not statistically significant (p = 0.55).
Change in hematocrit and liver biochemistry
The liver enzymes were measured pre- and post-dialysis.
There were significant changes in aspartate aminotransferase,
alkaline phosphatase, hematocrit and total bilirubin values.
The alanine aminotransferase and gamma-glutamyl transfer-
ase values were not significantly altered. After using the cor-
rection factor based on the published data by Schneditz et
al., however, we still found statistically significant
changes in some of the liver enzymes, including aspartate
transaminase, alkaline phosphatase and gamma-glutamyl
transpeptidase [21]. Please see Table 3. However, these
values did not correlate with the changes in liver water.
Discussion
We are unaware of other studies that specifically com-
pare the effects of HD with ultrafiltration related to liver
water content with peripheral and total body water.
Among the fourteen subjects, there was marked vari-
ation in liver water content pre-dialysis, surprisingly with
a lower value than expected compared to non-dialysis
subjects in other studies [22], even in those with fluid
overload. It has been shown that central volume is rela-
tively preserved with ultrafiltration but organ perfusion
is vulnerable to smaller shifts in hemodynamic stability
[23, 24]. In our study, whilst MR-measured peripheral
water content and commonly-used markers of overall
fluid status tended to correlate well with each other, there
was no demonstrable relationship between hepatic water
content and the majority of volume status markers.
Liver water was measured using an MR technique initially
designed to assess hepatic steatosis, by separating it from
water content. This technique has been validated in clinical
studies and employed in large randomized-controlled trials
[15–17]. The value reported represents water concentra-
tion. In the liver, as there is no significant extravascular,
extracellular space, this is a composite of intracellular fluid,
bile and largely intravascular volume. With regards to MR
imaging, we selected as large a region of interest as possible
at several different imaging slices, excluding major vessels.
Therefore, the changes in the liver water content was
unlikely due to imaging selection bias. There have been
several studies that assessed the splanchnic perfusion
during hemodialysis and they found that there were in-
creased hepato-splanchnic vasoconstriction with ultra-
filtration [10–12]. However, these studies only evaluated the
splanchnic vascular system. We are the first to report the ef-
fect of fluid removal during hemodialysis on intrahepatic
liver water content. Our paradoxical result, a non-significant
increase in liver water content, suggested that liver perfusion
is a complicated system and cannot be explained by chan-
ging in one vascular system, i.e. the splanchnic vasculature.
In addition, a recent pilot study showed an increased in
hepatic flow while a reduction in portal flow during dialysis
[25]. It may involve the hemodynamic changes in the
renal-gastro-hepatic axis with end stage renal disease, in
addition to amount of uremic solutes flow through the
hepatic system.
In health, in response to a reduction in circulating
volume, there is immediate contraction of liver volume
and expulsion of pooled blood. In this study, not only
did we observe that liver water content reduced to a
lesser extent than peripheral fluid, actually in many pa-
tients it increased. The changes in liver water content in
our subjects were larger than expected by the confidence
interval alone. Our observations suggest this physio-
logical reaction does not occur in all patients undergoing
HD. This response is not associated with comorbidities,
drugs (such as antiplatelet, antihypertensive and erythro-
poietin agents) and blood hematocrit, although our study
may be underpowered to really study this. This may be
due to differing levels of circulatory stress endured, with
some subjects not meeting the requirements for activation
of hepatic venoconstriction [25]. Another explanation is
that some subjects exhibited an abnormal hepatic re-
sponse to the circulatory stress of dialysis, with a diversion
of blood flow into the hepatic circulation. This is sup-
ported by the observation that liver water concentration
increased significantly more in patients who sustained a
considerable fall in their blood pressure during HD. The
negative impacts of ultrafiltration on myocardial perfusion
have been well described [26, 27]. The presence of both
cardiac and baseline autonomic dysfunction is also vari-
able in HD patients and this may additionally explain the
heterogeneity observed [28, 29].
Both passive distension and active venodilatation occur
in the face of hypervolaemia to accommodate additional
circulatory volume. Chronic congestion may lead to
increased hepatic size, but also leads to hepatic injury and
fibrosis, limiting the distensibility of liver tissue. It is
unclear whether patients with end-stage renal failure
undergoing regular dialysis develop chronic hepatic
congestion. In the majority of subjects in this study, liver
Table 3 The changes in the hematocrit, bilirubin and liver
enzymes values
Pre-dialysis Post-dialysis P-values
Aspartate aminotransferase, U/L 16 ± 3.8 21 ± 11.9 < 0.01
Alanine aminotransferase, U/L 12 ± 5.8 19 ± 17.8 0.58
Gamma-glutamyl transferase, U/L 23 ± 4.2 23 ± 5.7 0.95
Alkaline phosphatase, U/L 105 ± 47.1 111 ± 40.6 < 0.01
Total bilirubin, umol/L 4.19 ± 1.17 5.00 ± 1.56 < 0.01
Hematocrit, L/L 0.32 ± 0.04 0.35 ± 0.04 < 0.01
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stiffness was within the normal range, making significant
fibrosis unlikely. The liver enzymes were all within target
range. The changes in liver enzymes, hematocrit and
bilirubin before and after dialysis did not correlate with
the changes in liver water. The changes in these values
could be due to hemoconcentration post ultrafiltration.
Water concentration prior to HD was nevertheless highly
variable but with no clear relationship to MR-measured,
bioimpedance-derived or clinical assessments of fluid
status. Furthermore, all patients except one had normal
cardiac function with no significant valvular disease. There-
fore, cardiac dysfunction could not explain our findings.
One subject clinically appeared to be significantly
fluid-overloaded, yet their liver water concentration was
not elevated compared to other subjects. By contrast, their
peripheral water content measured by MRI followed the
appropriate responses to ultrafiltration. Such results suggest
that liver water concentration does not accurately reflect
fluid status in dialysis patients. In addition, liver water
concentration was inversely associated with one marker of
central volume status: IVC diameter. IVC size reflects
central venous pressure and is used as a marker of fluid
status. A higher IVC diameter is reflective of circulatory
volume overload, therefore one would expect the relation-
ship with liver water concentration to be the inverse of
what was observed.
Although the MRI technique has been used in other
non-dialysis studies, this pilot study was designed to ex-
plore the effects of HD upon liver congestion and, as
such, was not powered to conclusively establish trends,
therefore these results must be confirmed in larger stud-
ies. Furthermore, the MRI technique is associated with a
measurement error of 0.1 g/mL. As such, a value of 1.0
g/mL may actually reflect 0.9 g/mL. This may explain
the extreme values of liver water content. In addition, to
capture accurate measurements, breathing holding tech-
nique was used, which could also be a source of error if
the patients could not hold their breath for 20 s. These
are several limitations to consider which would be useful
to address when designing future studies. The relatively
small number of patients limited the statistical power to
do further subgroup analyses. However, it is not uncom-
mon for this type of translational research [10, 12]. We
did not measure cardiac function during the hemodialysis
as part of the study; however, static measures of cardiac
function did not show any significant cardiac dysfunction
prior to our study in these patients. Finally, subjects were
not fast for a specific time prior to and during dialy-
sis; ingestion of a large or lipid-rich meal in the few
hours prior to and during dialysis my have affected
individual results, as demonstrated by more recent
studies [30]. We did not assess other biomarkers,
such as vasopressin or copeptin, that may play a role
in hepato-splanchnic circulation in this population.
Further assessments of these biomarkers in the future
study should be considered.
Conclusions
In conclusion, we have shown that liver water content does
not reflect volume status in the hemodialysis patient, nor
does it reduce with ultrafiltration, unlike peripherally-held
volume. Instead, there appears to be a complex relationship
between liver water and hemodynamic stability during HD,
suggesting that the hepatic circulatory system plays a role
in the evolution of circulatory stress. Understanding the
physiology underlying this novel observation may help to
explain the hemodynamic response to HD.
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